The terms cannabinoids, terpenoids and flavonoids may not have the same market appeal as indica or sativa. But many industry experts say these secondary metabolites hold more value to cultivators and their customers than common strain names.
In the September 2019 issue of Cannabis Business Times, senior editor Brian MacIver explored some industry myths and how science is changing the way cultivators make strategic decisions (see the cover story “The Science Void”). It’s a topic that CBT also explored during the 2019 Cannabis Conference.
Andrea Sparr-Jaswa, now science editor at CBT and sister publication Cannabis Dispensary, addressed some of these key issues as the moderator for a panel on “Science That Sells: Debunking the Sativa and Indica Myths and Instead Focusing on Terpenoids, Cannabinoids and Flavonoids” at the 2019 event, which featured Jeremy Plumb, director of production science for Prf Cultivar; Jeremy Sackett, founder and chief science officer of Cascadia Labs; and Dr. Dominick Monaco, general manager at GB Sciences Inc.
Here are some highlights from the panel discussion and a glimpse at what’s to come for Cannabis Conference 2020 taking place at Paris Las Vegas April 21-23, 2020. (Note: the following has been edited for length and clarity.)
The “Science That Sells” panel from the 2019 Cannabis Conference. From left to right: Dominick Monaco, Jeremy Sackett, Jeremy Plumb and Andrea Sparr-Jaswa. Conference Photo by jake Gravbrot
On the Indica vs. Sativa Myth